文献速递白血病造血干细胞移植与细胞治疗

高亲和力组织蛋白酶G特异性CAR T细胞治疗急性髓系白血病

High-avidity cathepsin-G-specific CAR T cells for the treatment of acute myeloid leukemia.
PubMed 文献 · Blood · 2026-01-01

研究开发了针对HLA-A*02:01限制性髓系限制性组织蛋白酶G(CG)肽的CAR T细胞(CG1.CAR),并通过共表达LCK和重复CD3ζ链提高功能亲和力,使其可识别低至0.025μM的CG1肽。优化后的CG1.CAR T细胞在体外和患者来源AML异种移植小鼠模型中显示抗白血病效应,且在集落试验和人源化小鼠中未引起造血毒性。

要点

  • CG1.CAR T细胞靶向HLA-A*02:01限制性组织蛋白酶G肽,可识别低至0.025μM的肽。
  • 优化后的CG1.CAR T细胞在体外和体内均显示抗白血病效应。
  • 在集落试验和人源化小鼠中未观察到造血毒性。

核心结论

  • CG1.CAR T细胞基于临床前数据具有治疗急性髓系白血病的临床潜力。

研究设计与样本

  • 研究开发了针对HLA-A*02:01限制性组织蛋白酶G肽的CAR T细胞,并进一步工程化共表达LCK和重复CD3ζ链。
  • 在体外、患者来源AML异种移植小鼠模型、集落试验和人源化小鼠中评估了优化CG1.CAR T细胞。

主要发现

  • 优化后的CG1.CAR T细胞可功能性识别低至0.025μM的CG1肽。
  • 优化CG1.CAR T细胞在体外和患者来源AML异种移植小鼠模型中显示抗白血病效应。
  • 优化CG1.CAR T细胞在集落试验和人源化小鼠中未引起造血毒性。
  • LCK过表达导致线粒体编码电子传递链成分转录上调,与线粒体质量增加和呼吸能力改善相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T cells specific for myeloid-associated antigens expressed on the cell surface of acute myeloid leukemia (AML) can cause depletion of normal myeloid progenitor cells. We developed a CAR specific for an HLA-A∗02:01-restricted peptide of the myeloid-restricted cathepsin-G (CG) protein. CG-specific CAR T cells (CG1.CAR) were further engineered to increase their functional avidity. Specifically, we developed CG1.CAR T cells coexpressing the lymphocyte-specific protein tyrosine kinase (LCK) and duplicated CD3ζ chain, which allows the functional recognition of the CG1 peptide as low as 0.025μM. Optimized CG1.CAR T cells displayed antileukemia effects in vitro and in vivo in patient-derived AML xenotransplant mouse models and did not cause hematopoietic toxicity in colony assays and humanized mice. Mechanistically, LCK overexpression in CG1.CAR T cells caused transcriptional modifications characterized by the overexpression of mitochondrial-encoded electron transport chain components that were correlated with increased mitochondrial mass and improved respiratory capacity. Based on these data, CG1.CAR T cells hold clinical potential for the treatment of AML.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Walhart T, Biondi M, Stucchi S, et al. High-avidity cathepsin-G-specific CAR T cells for the treatment of acute myeloid leukemia. Blood. 2026. PMID: 42247309. doi:10.1182/blood.2025030577

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。